As a leading supplier of oligonucleotides, BOC Sciences is committed to providing our customers with comprehensive modification and labeling, offering affordable custom oligonucleotides or antibody-oligonucleotide conjugates.
Antibody-oligonucleotide Conjugates (AOCs) are novel targeted drugs consisting of chemically modified antibodies and oligonucleotides, which are highly specific and selective and can precisely target cancer cells, making them one of the hot topics of research.
The preparation of AOCs is based on the binding principle of antibodies to oligonucleotides. Antibodies are highly specific proteins that recognize and bind to target molecules, while oligonucleotides are sequence-specific molecules that match the mRNA sequences of target molecules. By combining oligonucleotides with antibodies, antibodies can be made to target cancer cells more precisely and achieve therapeutic effects.
The preparation methods of AOCs mainly include two kinds: one is to modify oligonucleotides into chemical groups that can bind to antibodies and then covalently bind to antibodies; the other is to use biological techniques to non-covalently bind oligonucleotides to antibodies, such as by DNA/RNA hybridization.
AOCs have very promising applications. They can be used to treat various types of cancers, such as breast cancer, colorectal cancer, lung cancer, etc. In addition, AOCs can be used to diagnose and predict cancer trends, providing a new means for precision medicine.
Compared with traditional chemotherapy drugs, AOCs have many advantages. First, they are highly specific and selective, and can precisely target cancer cells and reduce damage to normal cells. Second, AOCs have a long half-life, which can extend the duration of drug action. However, the research and application of AOCs still face many challenges, such as drug stability, drug metabolism and clearance, and other issues need to be further addressed.
In conclusion, AOCs are a kind of targeted drugs with great potential, and their application prospects are very broad. With the continuous development of related technologies, it is believed that AOCs will become one of the representatives of the new generation of targeted drugs.
Fig. 1 Schematic representation of AOC use in (a) antibody arrays; (b) therapeutic; and (c) pretargeting applications. (Dovgan, 2019)
| Service | Antibody-Oligonucleotide Conjugation |
| Customer provides | Oligonucleotide sequence |
| Purification | QC analysis by MS, HPLC, or PAGE |
| Delivery | Typical delivery is lyophilized samples in individual vials that are fully labeled |
| Request a Quote | Inquiry |
Reference
Browse Our Highlighted Services
Global Supplier of High-Quality RNA / DNA Products & Services.
